Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HNHA 是组蛋白去乙酰化酶抑制剂。它通过 p21诱导将细胞周期阻滞在 G1/S 期,抑制肿瘤生长及肿瘤新生血管形成。HNHA 可能是一种有效的抗乳腺癌药物。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 529 | 现货 | ||
2 mg | ¥ 771 | 现货 | ||
5 mg | ¥ 1,120 | 现货 | ||
10 mg | ¥ 2,120 | 现货 | ||
25 mg | ¥ 3,590 | 现货 | ||
50 mg | ¥ 5,180 | 现货 | ||
100 mg | ¥ 7,330 | 现货 | ||
500 mg | ¥ 14,600 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,220 | 现货 |
产品描述 | HNHA is an inhibitor of HDAC. |
靶点活性 | HDAC:100 nM |
体外活性 | Treatment of cells with HNHA could elicite histone hyperacetylation resulting in an up-regulation of cell cycle arrest, p21 transcription, and an inhibition of HT1080 cell invasion. HNHA was able to inhibit in-vitro HDAC enzyme activity as well as proliferation of human fibrosarcoma cells (HT1080). |
体内活性 | Several HDAC inhibitors, including MS-27-275 and a hydroxyamide-based HDAC inhibitors such as SAHA have been investigated extensively and shown to inhibit tumor growth in vivo. |
分子量 | 303.42 |
分子式 | C17H21NO2S |
CAS No. | 926908-04-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 15mg/mL(49.44mM)
DMSO: 15mg/mL(49.44mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 3.2958 mL | 16.4788 mL | 32.9576 mL | 82.394 mL |
5 mM | 0.6592 mL | 3.2958 mL | 6.5915 mL | 16.4788 mL | |
10 mM | 0.3296 mL | 1.6479 mL | 3.2958 mL | 8.2394 mL | |
20 mM | 0.1648 mL | 0.8239 mL | 1.6479 mL | 4.1197 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
HNHA 926908-04-5 Chromatin/Epigenetic DNA Damage/DNA Repair HDAC Histone deacetylases HIF/HIF Prolyl-Hydroxylase inhibit Inhibitor HIF-PH HIFs FM3A cells MCF-7 cells Anti-cancer activity Matrix metalloproteinases Breast cancer Hypoxia-inducible factors MMP inhibitor